Akero Therapeutics, Inc. filings document material-event reporting for a clinical-stage biotechnology company developing efruxifermin for MASH and other serious metabolic diseases. The company’s Form 8-K disclosures include operating and financial results, material agreements, shareholder voting matters, governance matters and capital-structure information.
Recent filing subjects include the company’s Nasdaq-listed common stock, quarterly results reporting and the termination of a material loan agreement following repayment of obligations to Hercules Capital. These regulatory records also describe formal exhibit filings, financial-condition updates and agreement-related changes affecting Akero’s public-company obligations.
Akero Therapeutics, Inc. (AKRO) Form 4 filing: Chief Technology Officer Scott A. Gangloff disclosed an automatic sale of 848 shares of common stock on 18 June 2025 at a weighted-average price of $54.84 per share. The transaction was executed under the company’s mandatory “sell-to-cover” policy to satisfy tax-withholding obligations triggered by the vesting of restricted stock units, meaning it was not a discretionary trade. After the sale, the executive continues to hold 23,452 shares directly.